Map Pharma plans IPO

Mountain View, CA-based MAP Pharmaceuticals announced that it is planning an IPO of 5 million shares of common stock at a price of between $14 and $16 per share. Money raised from the offering will be used to fund clinical work, among other things. MAP is developing inhaled drugs to treat pediatric asthma and migraines and is planning to launch two Phase III trial early next year.

- see the report from CNN Money

ALSO: Zars Pharma, a maker of topical pain relievers, has delayed its IPO until next week. Report

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.